Localisation of somatostatin and somatostatin receptors in benign and malignant ovarian tumours
| Autor: | Lindsay W. Turnbull, I Richmond, Stephen L. Atkin, L Helboe, Glen H. Hall |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2002 |
| Předmět: |
Adult
Cancer Research Pathology medicine.medical_specialty Stromal cell Biology somatostatin Adenocarcinoma angiogenesis medicine Humans Ovarian Diseases Receptors Somatostatin Receptor Aged Aged 80 and over Ovarian Neoplasms Neovascularization Pathologic Somatostatin receptor Molecular and Cellular Pathology Cancer Middle Aged medicine.disease Immunohistochemistry Gene Expression Regulation Neoplastic Somatostatin ovarian cancer Oncology somatostatin receptors Female Ovarian cancer |
| Zdroj: | British Journal of Cancer |
| ISSN: | 1532-1827 0007-0920 |
| Popis: | Somatostatin has been identified as having anti-proliferative, anti-angiogenic and pro-apoptotic actions in many tumour systems, and these effects are mediated through a family of five transmembrane G-protein coupled SRIF receptors. Ovarian cancer is the commonest gynaecological malignancy in the UK and maintenance therapy is urgently required. Native somatostatin expression and its receptors sst1,2,3 and 5 were studied with immunohistochemistry in 63 malignant and 35 benign ovarian tumours of various histological types. Fifty-seven out of 63 (90%) of malignant and 26/35 (74%) benign tumours expressed somatostatin. Receptors sst1,2,3 and 5 were expressed variably in epithelial, vascular and stromal compartments for both benign and malignant tumours. Somatostatin was found to correlate significantly with stromal sst1 (P=0.008), epithelial sst1 (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|